PMID- 32852696
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210118
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 11
IP  - 10
DP  - 2020 Oct
TI  - Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People >/= 65 
      Years Old with Type 2 Diabetes and Mild Renal Insufficiency.
PG  - 2419-2428
LID - 10.1007/s13300-020-00907-w [doi]
AB  - INTRODUCTION: Older patients with type 2 diabetes (T2D) are at increased risk of 
      diabetic nephropathy and mild renal insufficiency. This analysis compared the 
      anti-hyperglycemic efficacy and safety of sitagliptin with dapagliflozin in 
      patients >/= 65 years of age with T2D and mild renal insufficiency. METHODS: This 
      was a post hoc analysis of data from 410 patients >/= 65 years old who participated 
      in a 24-week, randomized, double-blind clinical trial (CompoSIT-R [comparison of 
      sitagliptin with dapagliflozin in mild renal impairment]; NCT02532855) in T2D 
      patients with mild renal insufficiency and on metformin +/- a sulfonylurea; the 
      primary efficacy end point was change in HbA1c at week 24. RESULTS: Treatment 
      groups were well balanced at baseline (mean HbA1c = 7.7/7.7% and 
      eGFR = 79/76 ml/min/1.73 m(2) for sitagliptin/dapagliflozin). At week 24, LS mean 
      (95% CI) change in HbA1c and percentage of patients with HbA1c < 7% were greater 
      with sitagliptin, - 0.48% and 41%, respectively, compared with dapagliflozin, 
      - 0.36% and 28%; between-group differences = - 0.12% (- 0.36, 0.01) and 12.8% 
      (3.3, 22.2) for change in HbA1c and percentage with HbA1c < 7%, respectively. The 
      sitagliptin group had greater reductions in PPG end points, while the 
      dapagliflozin group had greater reductions in FPG. Treatments were generally well 
      tolerated. There were fewer drug-related adverse events (AEs) with sitagliptin 
      than with dapagliflozin but AE profiles were otherwise similar. CONCLUSIONS: In 
      patients >/= 65 years of age with T2D and mild renal insufficiency with inadequate 
      glycemic control on metformin +/- sulfonylurea, treatment with sitagliptin for 
      24 weeks resulted in improvement in HbA1c relative to treatment with 
      dapagliflozin that is consistent with that previously observed in the overall 
      population. Both treatments were generally well tolerated.
FAU - Raji, Annaswamy
AU  - Raji A
AUID- ORCID: 0000-0002-2430-8160
AD  - Merck & Co., Inc., Kenilworth, NJ, USA. annaswamy.raji@merck.com.
FAU - Xu, Zhi Jin
AU  - Xu ZJ
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Lam, Raymond L H
AU  - Lam RLH
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - O'Neill, Edward A
AU  - O'Neill EA
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Kaufman, Keith D
AU  - Kaufman KD
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
FAU - Engel, Samuel S
AU  - Engel SS
AUID- ORCID: 0000-0002-4439-6356
AD  - Merck & Co., Inc., Kenilworth, NJ, USA.
LA  - eng
PT  - Journal Article
DEP - 20200827
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC7509009
OTO - NOTNLM
OT  - DPP-4
OT  - Elderly
OT  - Incretins
OT  - SGLT2
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
PMCR- 2020/08/27
CRDT- 2020/08/28 06:00
PHST- 2020/07/15 00:00 [received]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/27 00:00 [pmc-release]
AID - 10.1007/s13300-020-00907-w [pii]
AID - 907 [pii]
AID - 10.1007/s13300-020-00907-w [doi]
PST - ppublish
SO  - Diabetes Ther. 2020 Oct;11(10):2419-2428. doi: 10.1007/s13300-020-00907-w. Epub 
      2020 Aug 27.